Cancer Management and Research最新文献

{"title":"Hypopharyngeal Squamous Cell Carcinoma in Elderly Patients Aged ≥70 Years: Surgery and Postoperative Radiotherapy Improves Outcomes in Selected Patients.","authors":"Ru Wang, Ahmad A Hariri, Hengmin Tao, Yumei Wei, Zhenghua Lyu","doi":"10.2147/CMAR.S529332","DOIUrl":"10.2147/CMAR.S529332","url":null,"abstract":"<p><strong>Objective: </strong>To summarize the efficacy of surgery plus postoperative radiotherapy as initial treatment in elderly patients aged ≥70 years with advanced hypopharyngeal cancer and to analyze prognostic factors.</p><p><strong>Methods: </strong>Retrospective analysis of 77 elderly patients aged ≥70 years with stage III-IV hypopharyngeal squamous cell carcinoma who underwent surgery as initial treatment at Shandong Provincial ENT Hospital between 2006-2020. Treatment completion rate and prognostic factors were summarized and analyzed, with comparisons made to non-surgical treatments in published literature. SPSS 26.0 was used for analysis. Univariate Cox regression analysis was applied to identify potential predictors of overall survival (OS) and disease-free survival (DFS). Kaplan-Meier method with Log rank test was used to calculate and compare survival rates. Multivariate analysis employed the Cox proportional hazards regression model, with <i>P</i> < 0.05 considered statistically significant.</p><p><strong>Results: </strong>The study achieved 100% follow-up with a median duration of 62 months. Among the cohort, 26 patients received surgery only whilst 51 received surgery plus radiotherapy, seven patients failed to complete radiotherapy resulting in a completion rate of 86.27%. Survival analysis revealed significant intergroup differences: at 1 year, OS/DFS rates were 76.9%/73.1% in Group A versus 93.2%/81.8% in Group B (both <i>P</i> < 0.05). By 3 years, OS/DFS rates were 61.5%/57.7% in Group A versus 77.3%/70.5% in Group B. The overall 3-year and 5-year OS rates for the cohort were 68.8% and 52.3%, respectively. Univariate analysis showed no significant differences in gender, age, T/N staging, comorbidities, or second primary malignancies (all *<i>P</i>* > 0.05), but treatment modality was a significant predictor of both OS (<i>P</i> = 0.002) and DFS (<i>P</i> = 0.001). Multivariate COX regression analysis confirmed N staging and treatment modality as independent prognostic factors for OS (<i>P</i> = 0.007 and 0.002, respectively) and DFS (P = 0.009 and 0.002, respectively).</p><p><strong>Conclusion: </strong>Elderly hypopharyngeal cancer patients tolerated surgery and postoperative radiotherapy well. Active pursuit of comprehensive treatment is recommended for fit stage III-IV patients aged ≥70 years to improve outcomes.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1513-1523"},"PeriodicalIF":2.6,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ginseng-Derived Exosomes Attenuate Immune Evasion in NSCLC via PD-L1 Modulation.","authors":"Lin-Jia Zhu, Xiao-Qiang Chen, Qiu-Yan Lin, Jie-Ni Feng, Shao-Fei Yuan","doi":"10.2147/CMAR.S540462","DOIUrl":"10.2147/CMAR.S540462","url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. While PD-1/PD-L1 immune checkpoint blockade has shown promise, its efficacy is often limited by tumor-induced immune evasion. Ginseng-derived exosomes (G-Exos), as natural plant-based nanocarriers, may offer a novel strategy for immunomodulation. This study investigated the potential of G-Exos to regulate PD-L1 expression and enhance anti-tumor immunity in NSCLC.</p><p><strong>Methods: </strong>Exosomes were isolated from ginseng cell cultures and characterized via transmission electron microscopy and nanoparticle tracking analysis. Uptake by NSCLC cells was confirmed using PKH26 labeling. In vitro, NSCLC cells were co-cultured with activated T cells to evaluate cytotoxicity (colony formation), cytokine secretion [enzyme-linked immunosorbent assay (ELISA)], and T-cell activation (flow cytometry). PD-L1 expression was assessed by quantitative polymerase chain reaction (qPCR) and Western blot. In vivo, C57BL/6 mice (n = 20) bearing Lewis lung carcinoma (LLC) tumors were randomized into four groups (n = 5/group): PBS, G-Exos (10 μg), anti-PD-L1 (8 μg), or combination therapy. Treatments were administered intravenously every other day for 20 days. Tumor growth was measured, and tissues were analyzed by immunohistochemistry and flow cytometry.</p><p><strong>Results: </strong>G-Exos were efficiently internalized by NSCLC cells and demonstrated immunostimulatory properties in vitro. They enhanced T-cell-mediated cytotoxicity, as reflected by reduced tumor colony formation, and promoted immune activation, evidenced by increased IL-2 and IFN-γ secretion and a higher proportion of CD8⁺ T cells expressing TNF-α and perforin. Mechanistically, G-Exos downregulated PD-L1 expression at both transcriptional and translational levels in NSCLC cells. In vivo, G-Exos treatment significantly inhibited tumor growth and, when combined with anti-PD-L1 monoclonal antibody, exhibited a synergistic effect characterized by greater tumor suppression and increased infiltration of cytotoxic CD8⁺ T cells in the tumor microenvironment.</p><p><strong>Conclusion: </strong>Ginseng-derived exosomes downregulate PD-L1 and enhance T-cell function, counteracting immune evasion in NSCLC. Their synergy with anti-PD-L1 therapy supports their potential as adjuvant nanotherapeutics in cancer immunotherapy.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1503-1512"},"PeriodicalIF":2.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xingxiao Pill Suppressed the Progression of Non-Small Cell Lung Cancer by Targeting SREBP1/FASN-Induced Fatty Acid Biosynthesis via PI3K/AKT/mTOR Signaling Pathway.","authors":"Xiangnan Zhou, Xiuhua Hu, Zhiying Zhang, Shicheng Lin, Ximing Lin, Tian Zhou, Yanping Bai, Kaiwen Hu","doi":"10.2147/CMAR.S510010","DOIUrl":"10.2147/CMAR.S510010","url":null,"abstract":"<p><strong>Introduction: </strong>Xingxiao Pill (XXP), a typical traditional Chinese medicine (TCM) prescription drug used to treat NSCLC in clinic. However, the mechanism underlying its regulatory effects remains unclear. This study aimed to evaluate the potential efficacy of XXP in treating NSCLC and to investigate how XXP regulates fatty acid biosynthesis in NSCLC.</p><p><strong>Methods: </strong>A lung carcinoma mouse model was created by transplanting Lewis lung carcinoma (LLC) cells into male C57BL/6 mice. Lung cancer cell models using LLC and A549 cells were also constructed. XXP's therapeutic efficacy on NSCLC was assessed via oral gavage. Bioinformatics analysis and transcriptome sequencing identified XXP's potential targets and mechanisms. These findings were verified by in vitro cell assays, Western blotting, immunofluorescence staining, and Oil Red O staining.</p><p><strong>Results: </strong>XXP inhibited lung tumor growth, suppressed cell proliferation and impeded cell migration. Additionally, it influenced the processes of apoptosis and cell cycle in both A549 and LLC cells. Bioinformatics analysis suggested that regulation of fatty acid biosynthesis and phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway were crucial mechanisms underlying the antitumor effects of XXP in lung cancer. XXP reduced the levels of the fatty acid biosynthesis products, such as total cholesterol (TC), triglycerides (TG), lipids, and free fatty acids in A549 cells, and downregulated the expression of sterol regulatory element binding protein 1 (SREBP1) and fatty acid synthase (FASN). Furthermore, XXP decreased the expression level of PI3K, AKT, mTOR, phospho-PI3K, and phospho-AKT.</p><p><strong>Discussion: </strong>XXP exerts its inhibitory effect on lung cancer tumor growth by controlling the biosynthesis of fatty acids and the PI3K/AKT/mTOR signaling pathway. The research suggests that targeting this metabolic pathway could be a viable strategy for cancer therapy and emphasizes the value of TCM in providing a rich source of innovative pharmaceuticals for cancer treatment.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1487-1501"},"PeriodicalIF":2.6,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Artificial Intelligence and Radiomics in the Management of Lymphomas by PET/CT: The Clairvoyance in Clinic.","authors":"Chong Ling Duan, Lin An, Yong Feng Yang, Lili Yuan, Yandong Zhu, Qian Han, Hongbing Ma, Fei Zhao, Qing-Qing Yu","doi":"10.2147/CMAR.S529589","DOIUrl":"10.2147/CMAR.S529589","url":null,"abstract":"<p><p>Lymphomas are a hematopoietic malignancies that encompass over 90 subtypes. Traditionally, they have been categorized into two main groups, non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). Based on morphology and immunohistochemistry, HL can be classified into nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and classical HL (cHL). NHL represents the most common form of lymphoma, including more than 50 subtypes, such as mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), and the most common, diffuse large B-cell lymphoma (DLBCL). Medical imaging plays a pivotal role in lymphoma management, with positron emission tomography/computed tomography (PET/CT) serving as an indispensable tool. 2-Deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG) PET/CT is extensively utilized in lymphoma management, having demonstrated its value in providing crucial data for precise disease burden quantification, treatment response evaluation, and prognostic assessment. Radiomics is an innovative approach that entails the computer-aided extraction of quantitative, searchable data from medical images and its association with biological and clinical outcomes. The rapid advancement of radiomics research has opened new avenues for cancer diagnosis and therapy. Our findings indicate that artificial intelligence based PET/CT radiomics has demonstrated significant potential in lymphoma diagnosis, subtyping, staging, treatment selection, and survival prognosis assessment, offering clinicians powerful decision-support tools. However, challenges remain, such as the lack of standardized image quality in machine learning applications.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1457-1475"},"PeriodicalIF":2.5,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of Tumor ERCC1 Expression for Treatment Outcomes After Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer.","authors":"Masao Nakata, Shinsuke Saisho, Junichi Soh, Norihito Okumura, Hiroshige Nakamura, Motohiro Yamashita, Shinichi Toyooka, Hiroshi Date","doi":"10.2147/CMAR.S517916","DOIUrl":"10.2147/CMAR.S517916","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the predictive value of tumor expression of the excision repair cross-complementation group 1 gene (ERCC1) for the treatment outcomes after platinum-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>In this study, we conducted immunohistochemical analysis using a mouse monoclonal anti-ERCC1 antibody (clone 8F1) of operative specimens obtained from 238 patients enrolled in the SLCG0401 study which compared paclitaxel plus carboplatin (CBDCA+PTX) with uracil-tegafur (UFT) as adjuvant chemotherapy for stage IB-IIIA NSCLC. The overall survival (OS) of the patients was compared according to the ERCC1 expression status and adjuvant chemotherapy employed.</p><p><strong>Results: </strong>Of the 238 specimens, 102 (42.9%) showed a positive result for ERCC1 expression. There were no significant differences in the patient characteristics or OS between the tumor ERCC1-positive and -negative patient groups. Among the patients with ERCC1-negative tumors, there was no significant difference in the survival between patient groups treated with CBDCA+PTX and UFT (HR=0.932, 95% CI: 0.52-1.67, p=0.814). However, among the patients with ERCC1-positive tumors, CBDCA+PTX treatment tended to yield an inferior outcome, in terms of the OS, as compared with UFT treatment (HR=1.852, 95% CI: 0.92-3.73, p=0.080). Multivariate analysis showed that ERCC1 expression was not an independent predictor of the OS following CBDCA+PTX treatment in completely resected NSCLC patients.</p><p><strong>Conclusion: </strong>In completely resected NSCLC patients with positive tumor ERCC1 expression, adjuvant CBDCA+PTX treatment tended to yield an inferior outcome as compared with UFT treatment in terms of the OS. However, immunohistochemical analysis with the 8F1 antibody cannot be used for clinical decision making at this point.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1477-1486"},"PeriodicalIF":2.5,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Radiomics Nomogram Based on Magnetic Resonance Imaging and Clinicoradiological Factors to Predict HCC TACE Refractoriness.","authors":"YuHan Dong, Jihong Hu, Xuerou Meng, Bin Yang, Chao Peng, Wei Zhao","doi":"10.2147/CMAR.S486561","DOIUrl":"10.2147/CMAR.S486561","url":null,"abstract":"<p><strong>Purpose: </strong>This study constructs a predictive model for hepatocellular carcinoma (HCC) transarterial chemoembolization (TACE) refractoriness using a machine learning (ML) algorithm and verifies the predictive performance of different algorithms.</p><p><strong>Patients and methods: </strong>Clinical and magnetic resonance imaging (MRI) data of 131 patients (48 with TACE refractoriness) who underwent repeated TACE treatment for HCC were retrospectively collected. The training and validation cohorts comprised 104 and 27 cases, respectively, following an 8:2 ratio. Clinical imaging characteristics related to TACE refractoriness were identified through logistic regression analysis. HCC lesions on arterial phase, portal phase, delayed phase, and T2-weighted fat suppression MRI images before the first TACE were manually delineated as regions of interest. Dimension reduction was conducted using variance threshold, univariate selection, and least absolute shrinkage and selection operator methods. Relevant indices of TACE refractoriness were selected. ML algorithms, including a support vector machine, random forest, logistic regression and adaptive boosting, were used to construct the radiomics, clinical prediction, and combined models. The predictive performance of these models was evaluated using receiver operating characteristic curves. The optimal model was presented as a nomogram and verified through calibration and decision curve analyses.</p><p><strong>Results: </strong>In evaluating radiomics models for predicting TACE refractoriness in HCC, the LR-developed portal venous phase (VP) model achieved optimal single-sequence performance (training AUC: 0.896, 95% CI: 0.843-0.941; validation: 0.853, 0.727-0.965). Multisequence models significantly surpassed single-sequence counterparts, with the T2WI-FS+AP+VP+DP multisequence LR model demonstrating peak efficacy (training: 0.905, 0.853-0.949; validation: 0.876, 0.773-0.976). The integrated clinical-radiomics model demonstrated robust predictive performance, achieving a training cohort AUC of 0.955 (95% CI: 0.918-0.984) with 0.885 accuracy, 0.921 sensitivity, and 0.864 specificity, and maintained strong validation performance (AUC=0.941, 95% CI: 0.880-0.991).</p><p><strong>Conclusion: </strong>Multisequence clinical-radiomics model accurately predicts TACE refractoriness in hepatocellular carcinoma.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1441-1455"},"PeriodicalIF":2.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12279063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Pathogenesis and Prevention Strategies of Radiation-Induced Brain Injury.","authors":"Yong Wang, Jun Wu, Ya Wang, Weiyuan Song, Hongjian Ren, Xu Han, Xiaoqi Dong, Zhiqiang Guo","doi":"10.2147/CMAR.S525791","DOIUrl":"10.2147/CMAR.S525791","url":null,"abstract":"<p><p>Radiation-induced brain injury (RBI) encompasses the severe symptoms resulting from radiation-induced damage to the normal tissue surrounding tumors in patients undergoing radiotherapy for head and neck malignancies. The primary symptoms include skin erythema, pain, and may extend to headache, syncope, nausea, vomiting, memory impairment, alterations in mental status, visual disturbances, drowsiness, and other neurological abnormalities localized to the area of treatment. These side effects both limit the effectiveness of radiation therapy and reduce the patient's quality of life. During radiotherapy, while killing tumor cells, the radiation will damage the cerebral microvascular endothelial cells, cause cerebrovascular inflammatory response, destroy the blood-brain barrier, aggravate the cerebral oxidative stress response, and induce apoptosis of nerve cells. This review summarizes the mechanisms underlying the occurrence and progression of radiation-induced brain injury and discusses promising strategies for prevention and treatment that may be applicable to clinical patients suffering from this condition.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1433-1440"},"PeriodicalIF":2.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Value of Low-Dose Spiral CT Combined with Serum CEA in the Differential Diagnosis of Early Lung Cancer.","authors":"Jianguo Jin, Liping Wu","doi":"10.2147/CMAR.S516235","DOIUrl":"10.2147/CMAR.S516235","url":null,"abstract":"<p><strong>Purpose: </strong>Early detection of lung cancer is critical to improving prognosis, yet current screening methods such as low-dose spiral CT and serum CEA each have diagnostic limitations. This study aims to analyze the clinical value of low-dose spiral CT combined with serum CEA in the differential diagnosis of early lung cancer.</p><p><strong>Materials and methods: </strong>In this retrospective study, 62 patients diagnosed with early lung cancer in our hospital from April 2022 to October 2023 were selected as the case group, and 50 patients diagnosed with benign pulmonary lesions during the same period were selected as the control group. Data from low-dose spiral CT and serum CEA levels were compared. The efficacy of low-dose spiral CT alone, serum CEA alone, and the combination of both in discriminating early lung cancer was assessed using ROC curves.</p><p><strong>Results: </strong>Low-dose spiral CT showed a sensitivity of 77.42%, a specificity of 94.00%, and an AUC of 0.8571 (95% CI: 0.7832-0.9310) in detecting early lung cancer. Serum CEA levels were significantly higher in the case group compared to the control group (P<0.05). Serum CEA yielded an AUC of 0.8661 (95% CI: 0.7964-0.9359) in distinguishing early lung cancer (P<0.0001). Low-dose spiral CT combined with serum CEA detection achieved an AUC of 0.9137 (95% CI: 0.8624-0.9650), significantly increasing the early lung cancer detection rate from 82.26% to 95.16% (P<0.05).</p><p><strong>Conclusion: </strong>Patients with early lung cancer show distinct alterations in low-dose spiral CT signs, and their serum CEA levels demonstrate a notable increase compared with those with benign pulmonary lesions. The combination of low-dose spiral CT with serum CEA can be considered in the discrimination of early lung cancer, which can markedly enhance the positive detection rate while maintaining a minimal rise in false-positive rates.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1421-1432"},"PeriodicalIF":2.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Chain Mediating Role of Hope and Posttraumatic Growth Between Social Support and Psychological Distress Among Lung Cancer Patients.","authors":"Jin-Gui Huang, Chen-Han Xu, Yu-Mei Shi, Juan Jiang, Feng-Mei Huang, Ling-Li Xu","doi":"10.2147/CMAR.S522791","DOIUrl":"10.2147/CMAR.S522791","url":null,"abstract":"<p><strong>Purpose: </strong>This research was designed to explore whether hope and posttraumatic growth (PTG) played a mediating role between social support and psychological distress in patients diagnosed with lung cancer.</p><p><strong>Patients and methods: </strong>A hospital-based cross-sectional study was carried out on 502 lung cancer patients. From September 2023 to April 2024, participants were recruited via convenience sampling from one tertiary cancer hospital and two tertiary general hospitals in Chongqing, China. Patients completed questionnaires on demographics, medical information, Distress thermometer, Perceived Social Support Scale, Posttraumatic Growth Inventory, and Herth Hope Index. Statistical analyses included Pearson's chi-squared test or Fisher's exact test for differences in patient characteristics by psychological distress level. Pearson correlation analysis explored relationships among variables. Bootstrapping in structural equation modeling (SEM) evaluated structural paths, and multi-group SEM analysis tested the moderating effect of gender.</p><p><strong>Results: </strong>43.6% (219/502) of lung cancer patients experience psychological distress. After controlling for cancer stage and distant metastasis, the results suggested that social support had a negative direct effect on psychological distress. In addition, social support could also influence psychological distress via three pathways: (1) the mediating effect of hope, (2) the mediating effect of PTG, and (3) the serial mediating effect of hope and PTG. The indirect effect of the three intermediary paths accounted for 72.7% of the total effect. Gender moderated the effect of social support on PTG (<i>β</i> = -0.286, <i>P</i> = 0.001).</p><p><strong>Conclusion: </strong>This study found that lung cancer patients exhibit high levels of psychological distress. Social support directly impacts psychological distress and acts through multiple pathways: the mediating effects of hope and PTG, as well as their serial mediation. These findings deepen our understanding of how social support affects psychological distress in lung cancer patients and its underlying mechanisms, providing empirical support for developing interventions to alleviate distress.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1399-1419"},"PeriodicalIF":2.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Loop-Structure-Based CD19/CD22 Dual-Target CAR-T Therapy for High-Risk Diffuse Large B-Cell Lymphoma Presenting with Hemophagocytic Lymphohistiocytosis: A Case Report.","authors":"Yuan Ye, Shuhong Li, Zhi Guo, Lijun Zhao, Huanhuan Zhou, Nan Zhong, Mingxin He, Yu J Cao, Liqiong Liu","doi":"10.2147/CMAR.S521944","DOIUrl":"10.2147/CMAR.S521944","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of novel loop-structure-based CD19/CD22 dual-target chimeric antigen receptor T-cell (CD19/CD22 BS LoopCAR-T) therapy in high-risk diffuse large B-cell lymphoma (DLBCL) presenting with hemophagocytic lymphohistiocytosis (HLH).</p><p><strong>Methods: </strong>We analyzed the clinical data of a high-risk DLBCL patient presenting with HLH treated with CD19/CD22 BS LoopCAR-T at the Affiliated Nanshan Hospital of Shenzhen University in December 2023.</p><p><strong>Results: </strong>The patient, a 59-year-old female, was diagnosed with myelodysplastic syndromes with multilineage dysplasia in October 2022. Following six cycles of azacitidine treatment, her bone marrow and hemogram returned to normal, and the disease was stable In August 2023, she presented with recurrent fever for over a month and was diagnosed with high-risk DLBCL stage IVB presenting with HLH. After receiving the HLH-1994 protocol followed by one cycle each of R-CHOP and R-DA-EPOCH regimens, the patient underwent infusion of CD19/CD22 BS LoopCAR-T cells at a dose of 1.73×10⁸ cells. She experienced a rapid response, developing grade 1 cytokine release syndrome (CRS) and no immune effector cell-associated HLH-like syndrome (IEC-HS), and achieved disease stabilization following aggressive treatment. Bone marrow and peripheral blood flow cytometry at one and three months post-CAR-T therapy showed complete remission (CR). PET-CT at three months post-CAR-T therapy also indicated CR. The patient was followed up until April 2025, and the disease-free survival time after CAR-T treatment exceeded 16 months.</p><p><strong>Conclusion: </strong>The novel CD19/CD22 BS LoopCAR-T therapy is safe and effective in treating high-risk DLBCL patients presenting with HLH.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1389-1398"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}